BIIB Q2 2026 Earnings Call Summary

Biogen (BIIB) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $2.7 billion, up 3% year-over-year.
Core Pharmaceutical Revenue: $1.8 billion, up 4% year-over-year and 12% quarter-over-quarter.
Growth Portfolio Revenue: Over $1 billion, up 24% year-over-year and 25% quarter-over-quarter.
SPINRAZA Revenue: $402 million, up 2% year-over-year and 7% quarter-over-quarter.
LEQEMBI Revenue: $184 million, up 15% year-over-year and 9% quarter-over-quarter.
SYFOVRE and Empaveli Revenue: Combined $128 million since acquisition on May 14, contributing significantly to growth.
Free Cash Flow: $408 million generated in Q2.
Non-GAAP Diluted EPS Guidance: Updated range of $12 to $13 for 2026, reflecting dilution from Apellis acquisition.

2. Strategic Updates and Business Highlights

Growth Portfolio Expansion: The growth portfolio now exceeds the legacy MS portfolio, driven by SPINRAZA high-dose, LEQEMBI, and new products from the Apellis acquisition.
Acquisition of Apellis: Integration is progressing well, with SYFOVRE and Empaveli expected to contribute to mid- to high-teens growth through at least 2028.
Pipeline Development: Five registrational Phase 3 trials expected in the next year, including studies in lupus (SLE and CLE) and Dravet syndrome.
Early-Stage Pipeline Rebuilding: Three INDs filed this year, with plans for six new programs, focusing on autoimmune diseases and early-stage development.

3. Forward Guidance and Outlook

Revenue Guidance: Total revenue guidance updated from a mid-single-digit percentage decrease to a mid-single-digit percentage increase for 2026.
Core Operating Expenses: Expected to be between $2.65 billion and $2.7 billion in the second half of 2026.
Long-Term Growth: Biogen aims to return to sustainable revenue growth, leveraging both the Apellis acquisition and a robust late-stage pipeline.

4. Bad News, Challenges, or Points of Concern

VUMERITY Revenue Decline: Revenue down 7% year-over-year, indicating potential market challenges.
Competitive Pressures: The market for MS treatments is becoming increasingly crowded, impacting the performance of products like the BTK inhibitor BIIB091.
Integration Risks: While the Apellis acquisition is progressing, there are inherent risks associated with integrating new products and teams.
Market Access Dynamics: Uncertainty remains regarding Part D coverage for LEQEMBI, which could affect patient access and adoption rates.

5. Notable Q&A Insights

SPINRAZA High-Dose Demand: Initial demand for high-dose SPINRAZA is exceeding expectations, with positive feedback from patients and physicians.
Lupus Trials Expectations: Biogen is confident in its lupus trials (TOPAZ-1 and TOPAZ-2) but acknowledges the challenges of high placebo responses in previous studies.
SYFOVRE Growth Strategy: The team is focusing on improving patient education and addressing discontinuation rates post-injection to enhance growth.
Felzartamab Potential: There is significant optimism around felzartamab's potential in AMR, with a strong unmet need and promising early data.

Overall, Biogen's Q2 2026 results reflect a positive trajectory in revenue growth, driven by strategic acquisitions and a strong pipeline, despite facing competitive pressures and market access challenges.

BIIB — Biogen Inc.